Terence Flynn, Biotech Analyst at Morgan Stanley, discusses Eli Lilly's recent stock boost and its designation as Morgan ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

The company said that it would be recruiting more than a 1,000 highly-skilled team members to strengthen its digital strategy ...

The company further said it plans to employ around 1,000 to 1,500 highly-skilled professionals including technology engineers ...

If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We ...

Eli Lilly establishes new global capability centre in Hyderabad, recruiting over 1,000 skilled team members for digital ...

Eli Lilly’s popular anti-obesity drug Zepbound could get a sales boost after the U.S. Medicare program decided to pay for its use to treat sleep apnea. The Centers f ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Bullish option flow detected in Eli Lilly (LLY) with 11,152 calls trading, 1.3x expected, and implied vol increasing almost 2 points to 39.19%.

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...